CIK 0000784199 · Large accelerated filer
ARTIVION, INC.
Sign in to watch- Ticker
- AORT
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 592417093
- Phone
- 7704193355
- Business address
- 1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
- Former names
- CRYOLIFE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,529,843
- in 3 filings
Net −$2,529,843. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-22 | Borgstrom Marna P Director | Grant or award | +6,325 | 49,088 | ||
| 2025-05-22 | BEVEVINO DANIEL J Director | Grant or award | +6,325 | 150,061 | ||
| 2025-05-22 | ACKERMAN THOMAS F Director | Grant or award | +6,325 | 149,896 | ||
| 2025-05-22 | Salveson Jon W Director | Grant or award | +6,325 | 129,840 | ||
| 2025-05-22 | Hoff Elizabeth A Director | Grant or award | +6,325 | 31,389 | ||
| 2025-05-22 | Burbank Jeffrey H Director | Grant or award | +6,325 | 53,796 | ||
| 2025-05-22 | Bullock James Director | Grant or award | +6,325 | 68,647 | ||
| 2025-05-21 | Holloway Jean F SVP, General Counsel | Sale | −9,926 | $29.00 | $288K | 187,258 |
| 2025-05-09 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | −5,737 | $29.13 | $167K | 110,143 |
| 2025-05-09 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | −4,811 | $29.13 | $140K | 105,332 |
| 2025-03-11 | Holloway Jean F SVP, General Counsel | Option exercise 10b5-1 | +19,092 | $21.55 | $411K | 215,204 |
| 2025-03-11 | Holloway Jean F SVP, General Counsel | Sale 10b5-1 | −18,020 | $23.61 | $426K | 197,184 |
| 2025-03-11 | Holloway Jean F SVP, General Counsel | Option exercise · Stock Options (Right to buy) 10b5-1 | −19,092 | 0 | ||
| 2025-03-11 | Davis John E Chief Commercial Officer | Option exercise 10b5-1 | +15,910 | $21.55 | $343K | 223,878 |
| 2025-03-11 | Davis John E Chief Commercial Officer | Sale 10b5-1 | −15,100 | $23.61 | $357K | 208,778 |
| 2025-03-11 | Davis John E Chief Commercial Officer | Option exercise · Stock Options (Right to buy) 10b5-1 | −15,910 | 0 | ||
| 2025-03-06 | Mackin James P President & CEO | Grant or award 10b5-1 | +115,701 | 878,107 | ||
| 2025-03-06 | Mackin James P President & CEO | Sale 10b5-1 | −17,739 | $24.80 | $440K | 860,368 |
| 2025-03-06 | Mackin James P President & CEO | Option exercise 10b5-1 | +75,615 | $21.55 | $1.6M | 935,983 |
| 2025-03-06 | Mackin James P President & CEO | Sale 10b5-1 | −70,700 | $24.76 | $1.8M | 865,283 |
Page 8 of 11 · 201 trades